Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149935 | 1.00 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL21802051 | 0.81 | SIGMAR1 (0.50) | SMN1; SMN2GNEMAPK1 | |
| SCHEMBL30911663 | 0.81 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL30911660 | 0.81 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL3239132 | 0.81 | HTR2C (0.54) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL1554586 | 0.81 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL947448 | 0.81 | HTR2C (0.54) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL5014381 | 0.79 | SMN1; SMN2 (0.64) | RAB9ANPC1SMN1; SMN2HTR2CALDH1A1 | |
| SCHEMBL947594 | 0.79 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2GNEHTR2C | |
| SCHEMBL31098634 | 0.79 | SMN1; SMN2 (0.48) | RAB9ANPC1SMN1; SMN2GNEHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601287-B1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIV PALACKEHO (CZ) | 2021-12-15 | — | — | EP | claimed |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-06-08 | — | — | US | claimed |
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-03-19 | — | — | US | claimed |
| EP-3601287-B1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIV PALACKEHO (CZ) | 2021-12-15 | — | — | EP | disclosed |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-06-08 | — | — | US | disclosed |
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-03-19 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2696683-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | Alzheimer's Institute of America, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | FLT3, CDK9, CDK6 | RAB9A 2773/4885NPC1 4570/4885SMN1; SMN2 4032/4885 |
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | RAB9A 4121/4885NPC1 1268/4885SMN1; SMN2 3119/4885 |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | RAB9A 2718/4885NPC1 1464/4885SMN1; SMN2 4619/4885 |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | FLT3, CDK9, CDK6 | RAB9A 2773/4885NPC1 4570/4885SMN1; SMN2 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.